Tuesday, September 19, 2017

503B Outsourcing Facilities Exposed to Civil Liability for Allegedly Compounding “Essential Copies” of Commercially Available Drugs September 19, 2017 | By: Jason M. McLaren, Esq., Pharm.

503B Outsourcing Facilities Exposed to Civil Liability for Allegedly ...

https://www.frierlevitt.com/.../503b-outsourcing-facilities-exposed-civil-liability-alleg...
5 hours ago - An outsourcing facility may use a bulk drug substance in compounding only if it appears on a list to be developed by FDA “for which there is a clinical need” (also known as the “503B Bulks List”) or, alternatively, “the drug compounded from such bulk drug substance” appears on the FDA's drug shortage list at the time ...
Post a Comment